Jack Allen
Stock Analyst at Baird
(1.56)
# 3,416
Out of 4,966 analysts
42
Total ratings
40.62%
Success rate
-6.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Maintains: Neutral | $0.25 → $1 | $1.97 | -49.24% | 4 | Jun 27, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.04 | +284.62% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.13 | +696.46% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.22 | +365.12% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $14.24 | +180.90% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $69.39 | +52.76% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $11.36 | +58.52% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $27.00 | +566.67% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $1.71 | +367.84% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $51.83 | +0.33% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $32.22 | +160.71% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $2.92 | +173.97% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.17 | +327.35% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.57 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.36 | +167.86% | 1 | Oct 7, 2021 |
Vor Biopharma
Jun 27, 2025
Maintains: Neutral
Price Target: $0.25 → $1
Current: $1.97
Upside: -49.24%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.04
Upside: +284.62%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.13
Upside: +696.46%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.22
Upside: +365.12%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $14.24
Upside: +180.90%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $69.39
Upside: +52.76%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $11.36
Upside: +58.52%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $27.00
Upside: +566.67%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $1.71
Upside: +367.84%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $51.83
Upside: +0.33%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $32.22
Upside: +160.71%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $2.92
Upside: +173.97%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.17
Upside: +327.35%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.57
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.36
Upside: +167.86%